10,142
Total Claims
$2.3M
Drug Cost
1,488
Beneficiaries
$1,551
Cost/Patient
Peer Comparison vs. 18,720 Cardiology providers
+2%
Cost per patient vs peers
$1,551 vs $1,524 avg
+18%
Brand preference vs peers
16.1% vs 13.7% avg
Brand vs Generic
84% generic
Brand: 1,630 claims · $2.1M
Generic: 8,512 claims · $205K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 814 | $1.1M |
| Rivaroxaban | 328 | $468K |
| Tafamidis | 12 | $273K |
| Sacubitril/Valsartan | 101 | $115K |
| Evolocumab | 61 | $83K |
| Alirocumab | 15 | $22K |
| Metoprolol Succinate | 700 | $14K |
| Flecainide Acetate | 190 | $13K |
| Dabigatran Etexilate Mesylate | 15 | $13K |
| Ticagrelor | 11 | $11K |
| Atorvastatin Calcium | 843 | $11K |
| Labetalol Hcl | 250 | $9,751 |
| Diltiazem Hcl | 169 | $9,171 |
| Candesartan Cilexetil | 54 | $8,057 |
| Losartan Potassium | 494 | $7,997 |
Prescribing Profile
65
Unique Drugs
$1.6M
Patient Profile
78
Avg Age
42%
Female
1.40
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data